摘要
目的:评价基质金属蛋白酶-1(matrix metalloproteinase-1,MMP-1)对富含血小板血浆(platelet-rich plasma,PRP)所诱导的兔眼实验性增生性玻璃体视网膜病变(proliferative vitreoretinopathy,PVR)增殖膜的降解作用。方法:健康成年有色家兔30只,采用日本大耳白兔动脉血制备富含血小板血浆(PRP)诱导家兔双眼PVR动物模型。A组玻璃体腔注入组织型纤溶酶原激活剂(tissue plasminogen activator,t-PA)12.5μg(0.05mL),B组注入t-PA12.5μg+MMP-1100ng(0.1mL),C组注入t-PA12.5μg+MMP-1800ng,各组均以右眼为实验眼,左眼注入等量BSS为对照,共观察28d。采用裂隙灯和间接眼底镜等方法行临床观察,PVR分级评分,闪光视网膜电图(F-ERG)b波波幅值评价注药前及注药后各时间点视网膜功能状态,光镜观察视网膜各层结构改变,电镜观察视网膜感光细胞超微结构变化。结果:C组注药后各时间点PVR级别与对照组比较差异有显著统计学意义(P<0.01);注药后各时间点F-ERGb波波幅值比较,B组及C组分别于对照组比较差异具统计学意义(P<0.05,P<0.01),注药后28d时,B组与C组比较差异也具有统计学意义(P<0.05),C组与正常F-ERGb波波幅值比较差异也具有统计学意义(P<0.05)。结论:MMP-1玻璃体腔注射能对实验性兔眼增生性玻璃体视网膜病变中的增殖膜产生一定的降解作用。
AIM.To evaluate the efficiency of matrix metalloproteinase-1 （ MMP-1 ） as degradation in the treatment of experimental proliferative vitreoretinopathy （PVR） induced by intravitreal injection of platelet-rich plasma（PRP）. METHODS： Among 2.4 × 10^11-4.0 × 10^11/L of platelet- rich plasma （draw off the arterial blood of Japanese albino rabbit） was injected into vitreous cavity of both eyes to induced PVR in 30 pigmented rabbits. 4 days following induction of PVR, the right eyes of group A, B,C received 12.5μg of t-PA 0.05mL,and after 15 minutes group B,C received 100,800ng of MMP-1 0. 1 mL respectively, the left eyes with infusion of a volumetric equivalent dose of BSS as control, for 28 days. The clinical observation of retina and vitreous was performed under slim-lamp and ophthalmoscope three times weekly after establish of model. PVR severity within the each groups was compared by score grading at 7 days,14 days,21 days and 28 days after injection of t-PA and MMP-1. The function status of the retina and the ultrastructure of the photoreceptors was evaluated by flash electroretinogram, histopathology and electron microscope. RESULTS： Significant difference of the mean PVR score （ P〈 0.01 ）was found after injection of MMP-1 800ng-treated eyes （ C group） at different times compared with control group, while the ERG-b wave was 65 ± 24 in MMP-1 100ng-treated eyes and 125 ± 14 in MMP-1 800ng-treated eyes at 28 days after operation with a significant difference between them （ P 〈 0. 05）, and compared with control group respectively there were significant difference （ P 〈 0.05, P〈0.01）. CONCLUSION.. These results suggest that intravitreous administration of MMP-1 800ng has an degradation effect on membrane of experimental proliferative vitreoretinopathy. Further research is needed to the safety of its application in the eyes.
出处
《国际眼科杂志》
CAS
2009年第5期843-847,共5页
International Eye Science
